{
  "id": 9536102,
  "title": "STAT+: Why Gilead can’t stop talking about its ambitions in immunology",
  "url": "https://urgent.news/2026/09/24/stat-why-gilead-cant-stop-talking-about-its-ambitions-in-immunology",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-24T10:30:00.000Z",
  "source": {
    "name": "STAT News",
    "slug": "stat-news",
    "url": "https://www.statnews.com/2026/09/24/gilead-immunology-inflammation-biotech-moderna-merck/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Gilead Sciences’ top executives have been emphatically bullish about the biotech’s years-long push to develop drugs for inflammatory and autoimmune diseases.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}